Literature DB >> 11404245

Partial restoration of defective chloride conductance in DeltaF508 CF mice by trimethylamine oxide.

H Fischer1, N Fukuda, P Barbry, B Illek, C Sartori, M A Matthay.   

Abstract

This study was designed to test the in vivo efficacy of the chemical chaperone trimethylamine oxide (TMAO) in correcting the Cl- transport defect in a mouse model of cystic fibrosis (CF). Rectal potential difference (RPD) measurements were done in matched wild-type and DeltaF508 CF mice. Mice were treated by subcutaneous injections of TMAO. Wild-type mice demonstrated a forskolin-stimulated, Cl--dependent hyperpolarization of -6.4 +/- 0.8 mV (n = 11), which was significantly increased to -13.1 +/- 1.4 mV after treatment with TMAO. DeltaF508 CF mice showed no significant responses to forskolin. Treatment with TMAO recovered a forskolin-activated RPD in DeltaF508 CF mice (-1.1 +/- 0.2 mV; n = 17) but not in CFTR null mice. The effects of TMAO were dose dependent, resulting in a slope of -0.4 +/- 0.1 mV x g(-1) x kg(-1) in DeltaF508 CF mice. The forskolin-stimulated RPD in TMAO-treated DeltaF508 CF mice was partially blocked by glibenclamide and further stimulated by apigenin. The total response to forskolin plus apigenin was -2.5 +/- 0.45 mV (n = 6 mice), corresponding to 39% of the response evoked by forskolin only in wild-type mice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11404245     DOI: 10.1152/ajplung.2001.281.1.L52

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  19 in total

Review 1.  Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis.

Authors:  Marina S Gelman; Ron R Kopito
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 2.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

3.  Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants.

Authors:  Ying Wang; Tip W Loo; M Claire Bartlett; David M Clarke
Journal:  Biochem J       Date:  2007-09-01       Impact factor: 3.857

4.  The iodide-transport-defect-causing mutation R124H: a δ-amino group at position 124 is critical for maturation and trafficking of the Na+/I- symporter.

Authors:  Viktoriya Paroder; Juan P Nicola; Christopher S Ginter; Nancy Carrasco
Journal:  J Cell Sci       Date:  2013-05-20       Impact factor: 5.285

Review 5.  Protein processing and inflammatory signaling in Cystic Fibrosis: challenges and therapeutic strategies.

Authors:  C N Belcher; N Vij
Journal:  Curr Mol Med       Date:  2010-02       Impact factor: 2.222

Review 6.  Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies.

Authors:  Ronald C Rubenstein
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

7.  Molecular and cellular effects of Tamm-Horsfall protein mutations and their rescue by chemical chaperones.

Authors:  Lijie Ma; Yan Liu; Tarek M El-Achkar; Xue-Ru Wu
Journal:  J Biol Chem       Date:  2011-11-22       Impact factor: 5.157

8.  Phenanthrolines--a new class of CFTR chloride channel openers.

Authors:  M Duszyk; L MacVinish; A W Cuthbert
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

9.  Trimethylamine-N-oxide acutely increases cardiac muscle contractility.

Authors:  Carlee I Oakley; Julian A Vallejo; Derek Wang; Mark A Gray; LeAnn M Tiede-Lewis; Tilitha Shawgo; Emmanuel Daon; George Zorn; Jason R Stubbs; Michael J Wacker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-04-03       Impact factor: 4.733

10.  Chemical and biological folding contribute to temperature-sensitive DeltaF508 CFTR trafficking.

Authors:  Xiaodong Wang; Atanas V Koulov; Wendy A Kellner; John R Riordan; William E Balch
Journal:  Traffic       Date:  2008-07-30       Impact factor: 6.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.